Aeroallergen-specific Immunotherapy and Biologics Co-administration: Cost-benefit Re-considerations are Urgently Needed

Recent Adv Inflamm Allergy Drug Discov. 2023;17(2):85-87. doi: 10.2174/2772270817666230320153734.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Allergens / therapeutic use
  • Biological Products* / therapeutic use
  • Cost-Benefit Analysis
  • Immunotherapy

Substances

  • Biological Products
  • Allergens